MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study

    R. Loureiro, J. Domingos, D. Peralta, J. Dean, J. Ferreira (Lisbon, Portugal)

    Objective: To test the applicability of a rehabilitation program for people with Parkinson´s disease that combines speech and motor exercises (The CNS Moving Voice Program).…
  • 2016 International Congress

    Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)

    Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…
  • 2016 International Congress

    Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias

    S.J. Sherman, T. Falk (Tucson, AZ, USA)

    Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review. Background: Repurposing drugs that have already been proven…
  • 2016 International Congress

    Best supportive care or palliative care for late stage Parkinsonian syndromes?

    S. Lorenzl, C. Richinger, C. Schmotz, G. Nübling (Salzburg, Austria)

    Objective: To ask whether best supportive care might be more suitable for patients with Parkinson's disease (PD) and Parkinsonian syndromes and their family than palliative…
  • 2016 International Congress

    Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study

    P. Havránková, J. Klempír, M. Fialová, A. Rezková, J. Petrtýl, V. Capek, E. Ruzicka, J. Roth, R. Jech (Praha, Czech Republic)

    Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…
  • 2016 International Congress

    Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study

    P.A. LeWitt, M.I. Freed, M. Leinonen, A. Sedkov, H. Murck (West Bloomfield, MI, USA)

    Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…
  • 2016 International Congress

    Improved motor functioning of people with Parkinson’s disease following dance intervention

    S.M. Simone, K.A. Beben, S.E. Maguire, C. Noudga, K.L.M. Martin, G.N. Luabeya, P. Dhami, R.J. Bar, J.F. DeSouza (Toronto, ON, Canada)

    Objective: To investigate the effectiveness of dance as an additional treatment for people with Parkinson's disease (PD). Background: Common pharmacological treatments for PD lessen the…
  • 2016 International Congress

    Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

    N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

    Objective: To determine whether smartwatch sensor data correlates with clinician-measured Parkinson's disease symptoms. Background: Data collected with smartwatches could be used for long-term, continuous assessment…
  • 2016 International Congress

    Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

    R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

    Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…
  • 2016 International Congress

    Efficacy of 4845 botulinum toxin (BoNT) treatment cycles, and clinical strategies after a failed cycle

    P. Tanvijit, A.P. Moore (Bangkok, Thailand)

    Objective: To explore 1) relationship between peak benefit and Duration of Adequate Response (DAR) after BoNT, 2) frequency & causes of secondary Treatment Failure (TF),…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley